img

Global Lacosamide Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Lacosamide Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Lacosamide (INN, formerly known as erlosamide, harkeroside, SPM 927, or ADD 234037), is a medication for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. It is marketed under the trade name Vimpat.
Due to the COVID-19 pandemic, the global Lacosamide market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Oral tablets accounting for % of the Lacosamide global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Adults segment is altered to an % CAGR throughout this forecast period.
The global key companies of Lacosamide include UCB, Teva, Amneal Pharmaceuticals, MSN Laboratories, Alembic Pharma, Glenmark, Aurobindo Pharma, Accord Healthcare and Mylan, etc. In 2022, the global top five players had a share approximately % in terms of revenue.
The United States Lacosamide market size was US$ million in 2022, while China size was US$ million. The proportion of the United States was % in 2022, while China percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period. As for the Europe Lacosamide landscape, Germany is projected to reach US$ million by 2034. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Lacosamide market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Lacosamide market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Lacosamide market. Readers of the report can become informed about current and future trends of the global Lacosamide market and how they will impact market growth during the forecast period.



By Company


UCB
Teva
Amneal Pharmaceuticals
MSN Laboratories
Alembic Pharma
Glenmark
Aurobindo Pharma
Accord Healthcare
Mylan
Sun Pharma
Apotex
Segment by Type
Oral tablets
Oral solution
Intravenous

Segment by Application


Adults
Pediatric patients
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Lacosamide in global and regional level.
Chapter 3Detailed analysis of Lacosamide companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Lacosamide revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lacosamide Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 Oral tablets
1.2.3 Oral solution
1.2.4 Intravenous
1.3 Market by Application
1.3.1 Global Lacosamide Market Growth Rate by Application: 2018 VS 2022 VS 2034
1.3.2 Adults
1.3.3 Pediatric patients
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Lacosamide Market Size (2018-2034)
2.2 Lacosamide Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2034
2.3 Global Lacosamide Market Size by Region (2018-2024)
2.4 Global Lacosamide Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Lacosamide Countries Ranking by Market Size
3 Lacosamide Competitive by Company
3.1 Global Lacosamide Revenue by Players
3.1.1 Global Lacosamide Revenue by Players (2018-2024)
3.1.2 Global Lacosamide Market Share by Players (2018-2024)
3.2 Global Lacosamide Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Lacosamide Revenue
3.4 Global Lacosamide Market Concentration Ratio
3.4.1 Global Lacosamide Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lacosamide Revenue in 2022
3.5 Global Key Players of Lacosamide Head office and Area Served
3.6 Global Key Players of Lacosamide, Product and Application
3.7 Global Key Players of Lacosamide, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Lacosamide Breakdown Data by Type
4.1 Global Lacosamide Historic Revenue by Type (2018-2024)
4.2 Global Lacosamide Forecasted Revenue by Type (2024-2034)
5 Global Lacosamide Breakdown Data by Application
5.1 Global Lacosamide Historic Market Size by Application (2018-2024)
5.2 Global Lacosamide Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Lacosamide Revenue by Company (2021-2024)
6.2 North America Lacosamide Revenue by Type (2018-2034)
6.3 North America Lacosamide Revenue by Application (2018-2034)
6.4 North America Lacosamide Revenue by Country (2018-2034)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Lacosamide Revenue by Company (2021-2024)
7.2 Europe Lacosamide Revenue by Type (2018-2034)
7.3 Europe Lacosamide Revenue by Application (2018-2034)
7.4 Europe Lacosamide Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Lacosamide Revenue by Company (2021-2024)
8.2 Asia Pacific Lacosamide Revenue by Type (2018-2034)
8.3 Asia Pacific Lacosamide Revenue by Application (2018-2034)
8.4 Asia Pacific Lacosamide Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Lacosamide Revenue by Company (2021-2024)
9.2 Latin America Lacosamide Revenue by Type (2018-2034)
9.3 Latin America Lacosamide Revenue by Application (2018-2034)
9.4 Latin America Lacosamide Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Lacosamide Revenue by Company (2021-2024)
10.2 Middle East and Africa Lacosamide Revenue by Type (2018-2034)
10.3 Middle East and Africa Lacosamide Revenue by Application (2018-2034)
10.4 Middle East and Africa Lacosamide Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 U.A.E
11 Company Profiles
11.1 UCB
11.1.1 UCB Company Details
11.1.2 UCB Business Overview
11.1.3 UCB Lacosamide Products and Services
11.1.4 UCB Lacosamide Revenue in Lacosamide Business (2018-2024)
11.1.5 UCB Lacosamide SWOT Analysis
11.1.6 UCB Recent Development
11.2 Teva
11.2.1 Teva Company Details
11.2.2 Teva Business Overview
11.2.3 Teva Lacosamide Products and Services
11.2.4 Teva Lacosamide Revenue in Lacosamide Business (2018-2024)
11.2.5 Teva Lacosamide SWOT Analysis
11.2.6 Teva Recent Development
11.3 Amneal Pharmaceuticals
11.3.1 Amneal Pharmaceuticals Company Details
11.3.2 Amneal Pharmaceuticals Business Overview
11.3.3 Amneal Pharmaceuticals Lacosamide Products and Services
11.3.4 Amneal Pharmaceuticals Lacosamide Revenue in Lacosamide Business (2018-2024)
11.3.5 Amneal Pharmaceuticals Lacosamide SWOT Analysis
11.3.6 Amneal Pharmaceuticals Recent Development
11.4 MSN Laboratories
11.4.1 MSN Laboratories Company Details
11.4.2 MSN Laboratories Business Overview
11.4.3 MSN Laboratories Lacosamide Products and Services
11.4.4 MSN Laboratories Lacosamide Revenue in Lacosamide Business (2018-2024)
11.4.5 MSN Laboratories Lacosamide SWOT Analysis
11.4.6 MSN Laboratories Recent Development
11.5 Alembic Pharma
11.5.1 Alembic Pharma Company Details
11.5.2 Alembic Pharma Business Overview
11.5.3 Alembic Pharma Lacosamide Products and Services
11.5.4 Alembic Pharma Lacosamide Revenue in Lacosamide Business (2018-2024)
11.5.5 Alembic Pharma Lacosamide SWOT Analysis
11.5.6 Alembic Pharma Recent Development
11.6 Glenmark
11.6.1 Glenmark Company Details
11.6.2 Glenmark Business Overview
11.6.3 Glenmark Lacosamide Products and Services
11.6.4 Glenmark Lacosamide Revenue in Lacosamide Business (2018-2024)
11.6.5 Glenmark Lacosamide SWOT Analysis
11.6.6 Glenmark Recent Development
11.7 Aurobindo Pharma
11.7.1 Aurobindo Pharma Company Details
11.7.2 Aurobindo Pharma Business Overview
11.7.3 Aurobindo Pharma Lacosamide Products and Services
11.7.4 Aurobindo Pharma Lacosamide Revenue in Lacosamide Business (2018-2024)
11.7.5 Aurobindo Pharma Lacosamide SWOT Analysis
11.7.6 Aurobindo Pharma Recent Development
11.8 Accord Healthcare
11.8.1 Accord Healthcare Company Details
11.8.2 Accord Healthcare Business Overview
11.8.3 Accord Healthcare Lacosamide Products and Services
11.8.4 Accord Healthcare Lacosamide Revenue in Lacosamide Business (2018-2024)
11.8.5 Accord Healthcare Lacosamide SWOT Analysis
11.8.6 Accord Healthcare Recent Development
11.9 Mylan
11.9.1 Mylan Company Details
11.9.2 Mylan Business Overview
11.9.3 Mylan Lacosamide Products and Services
11.9.4 Mylan Lacosamide Revenue in Lacosamide Business (2018-2024)
11.9.5 Mylan Lacosamide SWOT Analysis
11.9.6 Mylan Recent Development
11.10 Sun Pharma
11.10.1 Sun Pharma Company Details
11.10.2 Sun Pharma Business Overview
11.10.3 Sun Pharma Lacosamide Products and Services
11.10.4 Sun Pharma Lacosamide Revenue in Lacosamide Business (2018-2024)
11.10.5 Sun Pharma Lacosamide SWOT Analysis
11.10.6 Sun Pharma Recent Development
11.11 Apotex
11.11.1 Apotex Company Details
11.11.2 Apotex Business Overview
11.11.3 Apotex Lacosamide Products and Services
11.11.4 Apotex Lacosamide Revenue in Lacosamide Business (2018-2024)
11.11.5 Apotex Recent Development
12 Lacosamide Market Dynamics
12.1 Lacosamide Industry Trends
12.2 Lacosamide Market Drivers
12.3 Lacosamide Market Challenges
12.4 Lacosamide Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Lacosamide Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of Oral tablets
Table 3. Key Players of Oral solution
Table 4. Key Players of Intravenous
Table 5. Global Lacosamide Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 6. Global Lacosamide Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
Table 7. Global Lacosamide Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Lacosamide Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 9. Global Lacosamide Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Table 10. Global Lacosamide Revenue by Players (2018-2024) & (US$ Million)
Table 11. Global Lacosamide Market Share by Players (2018-2024)
Table 12. Global Top Lacosamide Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lacosamide as of 2022)
Table 13. Ranking of Global Top Lacosamide Companies by Revenue (US$ Million) in 2022
Table 14. Global 5 Largest Players Market Share by Lacosamide Revenue (CR5 and HHI) & (2018-2024)
Table 15. Global Key Players of Lacosamide, Headquarters and Area Served
Table 16. Global Key Players of Lacosamide, Product and Application
Table 17. Global Key Players of Lacosamide, Date of Enter into This Industry
Table 18. Mergers & Acquisitions, Expansion Plans
Table 19. Global Lacosamide Market Size by Type (2018-2024) & (US$ Million)
Table 20. Global Lacosamide Revenue Market Share by Type (2018-2024)
Table 21. Global Lacosamide Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 22. Global Lacosamide Revenue Market Share by Type (2024-2034)
Table 23. Global Lacosamide Market Size by Application (2018-2024) & (US$ Million)
Table 24. Global Lacosamide Revenue Market Share by Application (2018-2024)
Table 25. Global Lacosamide Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 26. Global Lacosamide Revenue Market Share by Application (2024-2034)
Table 27. North America Lacosamide Revenue by Company (2021-2024) & (US$ Million)
Table 28. North America Lacosamide Revenue by Type (2018-2024) & (US$ Million)
Table 29. North America Lacosamide Revenue by Type (2024-2034) & (US$ Million)
Table 30. North America Lacosamide Revenue by Application (2018-2024) & (US$ Million)
Table 31. North America Lacosamide Revenue by Application (2024-2034) & (US$ Million)
Table 32. North America Lacosamide Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 33. North America Lacosamide Revenue by Country (2018-2024) & (US$ Million)
Table 34. North America Lacosamide Revenue by Country (2024-2034) & (US$ Million)
Table 35. Europe Lacosamide Revenue by Company (2021-2024) & (US$ Million)
Table 36. Europe Lacosamide Revenue by Type (2018-2024) & (US$ Million)
Table 37. Europe Lacosamide Revenue by Type (2024-2034) & (US$ Million)
Table 38. Europe Lacosamide Revenue by Application (2018-2024) & (US$ Million)
Table 39. Europe Lacosamide Revenue by Application (2024-2034) & (US$ Million)
Table 40. Europe Lacosamide Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 41. Europe Lacosamide Revenue by Country (2018-2024) & (US$ Million)
Table 42. Europe Lacosamide Revenue by Country (2024-2034) & (US$ Million)
Table 43. Asia Pacific Lacosamide Revenue by Company (2021-2024) & (US$ Million)
Table 44. Asia Pacific Lacosamide Revenue by Type (2018-2024) & (US$ Million)
Table 45. Asia Pacific Lacosamide Revenue by Type (2024-2034) & (US$ Million)
Table 46. Asia Pacific Lacosamide Revenue by Application (2018-2024) & (US$ Million)
Table 47. Asia Pacific Lacosamide Revenue by Application (2024-2034) & (US$ Million)
Table 48. Asia-Pacific Lacosamide Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 49. Asia Pacific Lacosamide Revenue by Region (2018-2024) & (US$ Million)
Table 50. Asia Pacific Lacosamide Revenue by Region (2024-2034) & (US$ Million)
Table 51. Latin America Lacosamide Revenue by Company (2021-2024) & (US$ Million)
Table 52. Latin America Lacosamide Revenue by Type (2018-2024) & (US$ Million)
Table 53. Latin America Lacosamide Revenue by Type (2024-2034) & (US$ Million)
Table 54. Latin America Lacosamide Revenue by Application (2018-2024) & (US$ Million)
Table 55. Latin America Lacosamide Revenue by Application (2024-2034) & (US$ Million)
Table 56. Latin America Lacosamide Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 57. Latin America Lacosamide Revenue by Country (2018-2024) & (US$ Million)
Table 58. Latin America Lacosamide Revenue by Country (2024-2034) & (US$ Million)
Table 59. Middle East and Africa Lacosamide Revenue by Company (2021-2024) & (US$ Million)
Table 60. Middle East and Africa Lacosamide Revenue by Type (2018-2024) & (US$ Million)
Table 61. Middle East and Africa Lacosamide Revenue by Type (2024-2034) & (US$ Million)
Table 62. Middle East and Africa Lacosamide Revenue by Application (2018-2024) & (US$ Million)
Table 63. Middle East and Africa Lacosamide Revenue by Application (2024-2034) & (US$ Million)
Table 64. Middle East and Africa Lacosamide Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 65. Middle East and Africa Lacosamide Revenue by Country (2018-2024) & (US$ Million)
Table 66. Middle East and Africa Lacosamide Revenue by Country (2024-2034) & (US$ Million)
Table 67. UCB Company Details
Table 68. UCB Business Overview
Table 69. UCB Lacosamide Product and Services
Table 70. UCB Lacosamide Revenue in Lacosamide Business (2018-2024) & (US$ Million)
Table 71. UCB Lacosamide SWOT Analysis
Table 72. UCB Recent Development
Table 73. Teva Company Details
Table 74. Teva Business Overview
Table 75. Teva Lacosamide Product and Services
Table 76. Teva Lacosamide Revenue in Lacosamide Business (2018-2024) & (US$ Million)
Table 77. Teva Lacosamide SWOT Analysis
Table 78. Teva Recent Development
Table 79. Amneal Pharmaceuticals Company Details
Table 80. Amneal Pharmaceuticals Business Overview
Table 81. Amneal Pharmaceuticals Lacosamide Product and Services
Table 82. Amneal Pharmaceuticals Lacosamide Revenue in Lacosamide Business (2018-2024) & (US$ Million)
Table 83. Amneal Pharmaceuticals Lacosamide SWOT Analysis
Table 84. Amneal Pharmaceuticals Recent Development
Table 85. MSN Laboratories Company Details
Table 86. MSN Laboratories Business Overview
Table 87. MSN Laboratories Lacosamide Product and Services
Table 88. MSN Laboratories Lacosamide Revenue in Lacosamide Business (2018-2024) & (US$ Million)
Table 89. MSN Laboratories Lacosamide SWOT Analysis
Table 90. MSN Laboratories Recent Development
Table 91. Alembic Pharma Company Details
Table 92. Alembic Pharma Business Overview
Table 93. Alembic Pharma Lacosamide Product and Services
Table 94. Alembic Pharma Lacosamide Revenue in Lacosamide Business (2018-2024) & (US$ Million)
Table 95. Alembic Pharma Lacosamide SWOT Analysis
Table 96. Alembic Pharma Recent Development
Table 97. Glenmark Company Details
Table 98. Glenmark Business Overview
Table 99. Glenmark Lacosamide Product and Services
Table 100. Glenmark Lacosamide Revenue in Lacosamide Business (2018-2024) & (US$ Million)
Table 101. Glenmark Lacosamide SWOT Analysis
Table 102. Glenmark Recent Development
Table 103. Aurobindo Pharma Company Details
Table 104. Aurobindo Pharma Business Overview
Table 105. Aurobindo Pharma Lacosamide Product and Services
Table 106. Aurobindo Pharma Lacosamide Revenue in Lacosamide Business (2018-2024) & (US$ Million)
Table 107. Aurobindo Pharma Lacosamide SWOT Analysis
Table 108. Aurobindo Pharma Recent Development
Table 109. Accord Healthcare Company Details
Table 110. Accord Healthcare Business Overview
Table 111. Accord Healthcare Lacosamide Product and Services
Table 112. Accord Healthcare Lacosamide Revenue in Lacosamide Business (2018-2024) & (US$ Million)
Table 113. Accord Healthcare Lacosamide SWOT Analysis
Table 114. Accord Healthcare Recent Development
Table 115. Mylan Company Details
Table 116. Mylan Business Overview
Table 117. Mylan Lacosamide Product and Services
Table 118. Mylan Lacosamide Revenue in Lacosamide Business (2018-2024) & (US$ Million)
Table 119. Mylan Lacosamide SWOT Analysis
Table 120. Mylan Recent Development
Table 121. Sun Pharma Company Details
Table 122. Sun Pharma Business Overview
Table 123. Sun Pharma Lacosamide Product and Services
Table 124. Sun Pharma Lacosamide Revenue in Lacosamide Business (2018-2024) & (US$ Million)
Table 125. Sun Pharma Lacosamide SWOT Analysis
Table 126. Sun Pharma Recent Development
Table 127. Apotex Company Details
Table 128. Apotex Business Overview
Table 129. Apotex Lacosamide Product and Services
Table 130. Apotex Lacosamide Revenue in Lacosamide Business (2018-2024) & (US$ Million)
Table 131. Apotex Recent Development
Table 132. Lacosamide Market Trends
Table 133. Lacosamide Market Drivers
Table 134. Lacosamide Market Challenges
Table 135. Lacosamide Market Restraints
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
List of Figures
Figure 1. Lacosamide Product Picture
Figure 2. Global Lacosamide Market Size by Type (US$ Million): 2018 VS 2022 VS 2034
Figure 3. Global Lacosamide Market Share by Type: 2022 VS 2034
Figure 4. Oral tablets Features
Figure 5. Oral solution Features
Figure 6. Intravenous Features
Figure 7. Global Lacosamide Market Size by Application (US$ Million): 2018 VS 2022 VS 2034
Figure 8. Global Lacosamide Market Share by Application: 2022 VS 2034
Figure 9. Adults
Figure 10. Pediatric patients
Figure 11. Lacosamide Report Years Considered
Figure 12. Global Lacosamide Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 13. Global Lacosamide Market Size 2018-2034 (US$ Million)
Figure 14. Global Lacosamide Market Size Market Share by Region: 2022 VS 2034
Figure 15. Global Lacosamide Revenue Market Share by Region in 2018 VS 2022
Figure 16. Global Lacosamide Revenue Market Share Forecast by Region (2024-2034)
Figure 17. Global Top 10 Lacosamide Countries Ranking by Market Size (US$ Million) in 2022
Figure 18. Global Lacosamide Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Figure 19. Global Lacosamide Market Share by Players in 2022
Figure 20. Global Top Lacosamide Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lacosamide as of 2022)
Figure 21. The Top 10 and 5 Players Market Share by Lacosamide Revenue in 2022
Figure 22. North America Lacosamide Revenue Market Share by Company in 2022
Figure 23. North America Lacosamide Revenue Market Share by Type (2018-2034)
Figure 24. North America Lacosamide Revenue Market Share by Application (2018-2034)
Figure 25. North America Lacosamide Revenue Share by Country (2018-2034)
Figure 26. U.S. Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 27. Canada Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 28. Europe Lacosamide Revenue Market Share by Company in 2022
Figure 29. Europe Lacosamide Revenue Market Share by Type (2018-2034)
Figure 30. Europe Lacosamide Revenue Market Share by Application (2018-2034)
Figure 31. Europe Lacosamide Revenue Share by Country (2018-2034)
Figure 32. Germany Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 33. France Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 34. U.K. Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 35. Italy Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 36. Russia Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 37. Asia Pacific Lacosamide Revenue Market Share by Company in 2022
Figure 38. Asia Pacific Lacosamide Revenue Market Share by Type (2018-2034)
Figure 39. Asia Pacific Lacosamide Revenue Market Share by Application (2018-2034)
Figure 40. Asia Pacific Lacosamide Revenue Share by Region (2018-2034)
Figure 41. China Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 42. Japan Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 43. South Korea Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 44. India Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 45. Australia Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 46. Taiwan Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 47. Indonesia Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 48. Thailand Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 49. Malaysia Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 50. Philippines Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 51. Vietnam Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 52. Latin America Lacosamide Revenue Market Share by Company in 2022
Figure 53. Latin America Lacosamide Revenue Market Share by Type (2018-2034)
Figure 54. Latin America Lacosamide Revenue Market Share by Application (2018-2034)
Figure 55. Latin America Lacosamide Revenue Share by Country (2018-2034)
Figure 56. Mexico Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 57. Brazil Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 58. Argentina Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 59. Middle East and Africa Lacosamide Revenue Market Share by Company in 2022
Figure 60. Middle East and Africa Lacosamide Revenue Market Share by Type (2018-2034)
Figure 61. Middle East and Africa Lacosamide Revenue Market Share by Application (2018-2034)
Figure 62. Middle East and Africa Lacosamide Revenue Share by Country (2018-2034)
Figure 63. Turkey Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 64. Saudi Arabia Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 65. U.A.E Lacosamide Revenue (2018-2034) & (US$ Million)
Figure 66. UCB Revenue Growth Rate in Lacosamide Business (2018-2024)
Figure 67. Teva Revenue Growth Rate in Lacosamide Business (2018-2024)
Figure 68. Amneal Pharmaceuticals Revenue Growth Rate in Lacosamide Business (2018-2024)
Figure 69. MSN Laboratories Revenue Growth Rate in Lacosamide Business (2018-2024)
Figure 70. Alembic Pharma Revenue Growth Rate in Lacosamide Business (2018-2024)
Figure 71. Glenmark Revenue Growth Rate in Lacosamide Business (2018-2024)
Figure 72. Aurobindo Pharma Revenue Growth Rate in Lacosamide Business (2018-2024)
Figure 73. Accord Healthcare Revenue Growth Rate in Lacosamide Business (2018-2024)
Figure 74. Mylan Revenue Growth Rate in Lacosamide Business (2018-2024)
Figure 75. Sun Pharma Revenue Growth Rate in Lacosamide Business (2018-2024)
Figure 76. Apotex Revenue Growth Rate in Lacosamide Business (2018-2024)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed